Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH-2: Ramucirumab in HCC with elevated AFP
NCT02435433Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Jul 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02435433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435433.